Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 10/20 | 0.55 |
| ▸ | BCL2L1 | Q07817 | 6/20 | 0.55 |
| ▸ | BCL2L2 | Q92843 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1677855 | 0.94 | BCL2 (0.56) | BCL2BCL2L1BCL2L2 | |
| SCHEMBL1111924 | 0.92 | BCL2 (0.56) | BCL2BCL2L1BCL2L2 | |
| SCHEMBL27831700 | 0.91 | BCL2 (0.55) | BCL2BCL2L1BCL2L2 | |
| SCHEMBL1677621 | 0.88 | BCL2 (0.53) | BCL2BCL2L1BCL2L2 | |
| SCHEMBL1111798 | 0.87 | BCL2 (0.56) | BCL2BCL2L1BCL2L2 | |
| SCHEMBL1111919 | 0.85 | BCL2 (0.56) | BCL2BCL2L1BCL2L2 | |
| SCHEMBL1112009 | 0.85 | BCL2 (0.54) | BCL2BCL2L1BCL2L2 | |
| SCHEMBL1112004 | 0.83 | BCL2 (0.66) | BCL2BCL2L1BCL2L2 | |
| SCHEMBL1677546 | 0.83 | BCL2 (0.61) | BCL2BCL2L1BCL2L2 | |
| SCHEMBL1677774 | 0.82 | BCL2 (0.63) | BCL2BCL2L1BCL2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098305-A1 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | BAELL JONATHAN BAYLDON | 2011-04-28 | — | — | US | disclosed |
| EP-2279174-A2 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Genentech, Inc. (US) | 2011-02-02 | — | — | EP | disclosed |
| WO-2009143246-A2 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098305-A1 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | BAX, API5, BCL2 | BCL2 3/4885BCL2L1 13/4885BCL2L2 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.